WHY WAIT! Trademark

Trademark Overview


On Wednesday, June 12, 2024, a trademark application was filed for WHY WAIT! with the United States Patent and Trademark Office. The USPTO has given the WHY WAIT! trademark a serial number of 79403022. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Friday, September 5, 2025. This trademark is owned by Clinically Approved Holdings Pty Ltd. The WHY WAIT! trademark is filed in the Light Beverage Products and Pharmaceutical Products categories with the following description:

Vitamins; mineral supplements; nutritional supplements; multivitamin preparations; pharmaceutical preparations containing vitamins for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical preparations containing omega 3; pharmaceutical preparations for metabolic support; pharmaceutical preparations for the improvement of brain health, immunity, sleep, mood, gut health, women's health; pharmaceutical preparations containing vitamins for pregnancy; vitamin supplements; vitamin fortified beverages for medical use; vitamin preparations; medicines for treatment of heart diseases; pharmaceutical products for combating heart diseases; pharmaceutical tablets for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical tablets containing omega 3; pharmaceutical tablets for metabolic support; pharmaceutical tablets for the improvement of brain health, immunity, slee...

Non-alcoholic beverages, namely, carbonated beverages; concentrates and powders used in the preparation of soft drinks; drinking water
why wait!

General Information


Serial Number79403022
Word MarkWHY WAIT!
Filing DateWednesday, June 12, 2024
Status645 - FINAL REFUSAL - MAILED
Status DateFriday, September 5, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesVitamins; mineral supplements; nutritional supplements; multivitamin preparations; pharmaceutical preparations containing vitamins for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical preparations containing omega 3; pharmaceutical preparations for metabolic support; pharmaceutical preparations for the improvement of brain health, immunity, sleep, mood, gut health, women's health; pharmaceutical preparations containing vitamins for pregnancy; vitamin supplements; vitamin fortified beverages for medical use; vitamin preparations; medicines for treatment of heart diseases; pharmaceutical products for combating heart diseases; pharmaceutical tablets for the treatment of cardiovascular diseases, pain, skin conditions, cold and flu, joint and muscle diseases; pharmaceutical tablets containing omega 3; pharmaceutical tablets for metabolic support; pharmaceutical tablets for the improvement of brain health, immunity, sleep, mood, gut health, women's health; pharmaceutical tablets containing vitamins for pregnancy; anti-inflammatories; vitamin mineral and herbal preparations in tablet and powder form for medical use; dietary nutritional supplements; dietary supplements; dietetic drinks adapted for medical purposes; dietetic food supplements adapted for medical purposes; effervescent vitamin tablets; herbal extracts, other than essential oils, for medical purposes; food supplements, namely, antioxidants, omega 3; dietary food supplements; medicated food supplements; nutritionally fortified beverages adapted for medical purposes; therapeutic agents for weight control and appetite suppression; vitamin tablets; dietary supplements in powder form; medicinal drinks; dietary supplements in capsule form; dietary supplements in liquid capsule form; gummy vitamins; medicines and chemical compounds for the treatment and support of blood circulation; pharmaceutical preparations, medicines and chemical compounds for the treatment of cardiovascular diseases; pharmaceutical preparations, medicines and chemical compounds for the health of blood cells and production of blood lipids, pharmaceutical preparations, medicines and chemical compounds for treatment of cells exposed to oxidants; pharmaceutical preparations, medicines and chemical compounds to treat blood disorders; pharmaceutical preparations, medicines and chemical compounds to treat cardiovascular diseases and for cardiovascular health; chemical preparations for the treatment of cognitive decline; chemical preparations for the treatment of anxiety; chemical preparations for depression; pharmaceutical preparations for the treatment of alzheimers disease; pharmaceutical preparations for the treatment and management of coronavirus disease; pharmaceutical preparations for strengthening human immune responses; pharmaceutical preparations for treatment of influenza variations; pharmaceutical preparations for sleep support; mineral food supplements; analgesics and analgesic preparations; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat blood circulation, artery wellness and strong cardiovascular system, heart disease, healthy red blood cell production and healthy blood lipids, cell energy and to protect cells from oxidative damage and calcium absorption and to maintain healthy blood glucose, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat excessive immune response in relation to coronavirus disease, delivered in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to treat for excessive immune response in humans with influenza, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat Alzheimer's disease, age related mental decline, anxiety and depression, brain fog, stress, ADHD, slow memory and cognitive decline; analgesic preparations, medicines and chemical compounds to improve brain function, brain health during pregnancy and early childhood in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support, assist, relieve and treat joint pain, joint disease, arthritis, mild joint aches, and to maintain joint mobility and/or flexibility, healthy joint cartilage growth and/or joint health, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to support and assist sleep quality, sleep patterns, and the time required to fall asleep, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, medicines and chemical compounds to increase calmness, support healthy stress response in the human body, reduce stress and anxiety, relieve symptoms of stress, anxiety or nervous tension, in liquid, tablet, capsule, powder, tea and gummy form; analgesic preparations, and medicines and chemical compounds for the relief and treatment of pain, inflammation, discomfort and swelling in connection with or related to any body component including, without limitation, muscular aches and pains, backache, headache, migraine headache, tension headache, sinus pain, toothache, dental pain, period pain, sore throat, tennis elbow, rheumatic pain, aches and pains associated with colds and flu, female period pain, pain and sleep, pain in connection with manual and/or physical labour, and/or pain in connection with the recovery of injury, harm, decline and damage to any body component, delivered in liquid, tablet, capsule, powder, tea and gummy form; analgesics, medicines and chemical compounds to support and treat eye vision, age-related eye diseases, eye health, eye conditions including dry eye, aged-related Macular Degeneration and/or cataracts, in liquid, tablet, capsule, powder, tea and gummy form; analgesics, medicines and chemical compounds for the treatment of the health and quality of skin, cell growth and renewal, skin damage, skin wrinkle depth, skin hydration, skin appearance, in liquid, tablet, capsule, powder, tea and gummy form; analgesics, medicines and chemical compounds for the treatment of heart health, brain health, eye health, muscle health, joint health, colon, prostate and breast cancers, metabolic syndrome, in liquid, tablet, capsule, powder, tea and gummy form
Goods and ServicesNon-alcoholic beverages, namely, carbonated beverages; concentrates and powders used in the preparation of soft drinks; drinking water

Classification Information


International Class032 - Beers; mineral and aerated waters and other nonalcoholic drinks; fruit drinks and fruit juices; syrups and other preparations for making beverages.
US Class Codes045, 046, 048
Class Status Code6 - Active
Class Status DateThursday, August 29, 2024
Primary Code032
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 29, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameClinically Approved Holdings Pty Ltd
Party Type10 - Original Applicant
Legal Entity Type82 - NOT AVAILABLE
AddressAU

Trademark Events


Event DateEvent Description
Thursday, August 29, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, August 30, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 30, 2024APPLICATION FILING RECEIPT MAILED
Thursday, December 19, 2024NON-FINAL ACTION WRITTEN
Friday, December 20, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, January 15, 2025NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Tuesday, March 4, 2025REFUSAL PROCESSED BY MPU
Tuesday, March 4, 2025NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, December 18, 2024ASSIGNED TO EXAMINER
Wednesday, January 15, 2025NON-FINAL ACTION WRITTEN
Thursday, January 16, 2025NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, March 22, 2025REFUSAL PROCESSED BY IB
Tuesday, September 2, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 2, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 2, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 5, 2025FINAL REFUSAL WRITTEN
Friday, September 5, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, September 5, 2025FINAL REFUSAL E-MAILED